Inggris - Inggris - MHRA (Medicines & Healthcare Products Regulatory Agency)

medihealth (northern) ltd - yellow soft paraffin - cutaneous ointment - 1mg/1mg

Tanzania - Inggris - Tanzania Medicinces & Medical Devices Authority

chemoquip (t) ltd, tanzania - yellow tips -

Tanzania - Inggris - Tanzania Medicinces & Medical Devices Authority

najram limited, tanzania - yellow tips -

Tanzania - Inggris - Tanzania Medicinces & Medical Devices Authority

b & bj tanzania ltd, tanzania - yellow tips -

Inggris - Inggris - MHRA (Medicines & Healthcare Products Regulatory Agency)

bausch & lomb uk ltd - bromfenac sodium sesquihydrate - eye drops - 900microgram/1ml

Uni Eropa - Inggris - EMA (European Medicines Agency)

bausch + lomb ireland limited - bromfenac sodium sesquihydrate - pain, postoperative; ophthalmologic surgical procedures - ophthalmologicals - treatment of postoperative ocular inflammation following cataract extraction in adults.

Inggris - Inggris - MHRA (Medicines & Healthcare Products Regulatory Agency)

sanofi - yellow fever virus strain 17d - powder and solvent for suspension for injection

Selandia Baru - Inggris - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - yellow fever vaccine 1000 [iu] (17d strain);   - suspension for injection - 1000 iu - active: yellow fever vaccine 1000 [iu] (17d strain)   excipient: alanine calcium chloride dihydrate dibasic sodium phosphate dihydrate histidine hydrochloride lactose monohydrate magnesium sulfate heptahydrate monobasic potassium phosphate potassium chloride sodium chloride sodium hydroxide sorbitol purified water sodium chloride - prevention of yellow fever. vaccination is recommended for: · every person over 9 months of age living or travelling through an endemic area. · non-vaccinated persons moving from an endemic to a potentially receptive non-endemic area. · laboratory workers handling potentially infectious materials. · in order to be officially recognised, the yellow fever vaccination must be administered in an approved vaccination centre and registered on an international certificate. the validity period of the certificate is established according to international health regulations recommendations and starts 10 days after primary vaccination and immediately after re-vaccination.

Kanada - Inggris - Health Canada

seroyal international inc. - echinacea purpurea; goose grass; yellow dock; sarsaparilla; figwort; taraxacum officinale weber; trifolium pratense - globules - 1x; 1x; 1x; 1x; 1x; 1x; 1x - echinacea purpurea 1x; goose grass 1x; yellow dock 1x; sarsaparilla 1x; figwort 1x; taraxacum officinale weber 1x; trifolium pratense 1x - homeopathic products

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

wockhardt bio pty ltd - docetaxel, quantity: 160 mg - injection, concentrated - excipient ingredients: ethanol absolute; polysorbate 80; citric acid monohydrate - docetaxel concentrate for solution for infusion is indicated for;,breast cancer -,metastatic breast cancer : docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer in whom previous chemotherapy has failed. ,docetaxel in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy. ,docetaxel in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours overexpress her2 and who previously have not received chemotherapy for metastatic disease. ,adjuvant treatment of breast cancer : docetaxel in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with node-positive breast cancer. ,doxorubicin and cyclophosphamide followed by docetaxel in combination with trastuzumab (ac-th) is indicated for the adjuvant treatment of patients with operable breast cancer whose tumours overexpress her2. ,docetaxel in combination with carboplatin and trastuzumab (tch) is indicated for the adjuvant treatment of patients with operable breast cancer whose tumours overexpress her2. ,docetaxel in combination with cyclophosphamide is indicated for the adjuvant treatment of operable breast cancer with a primary tumour of ? 1cm and < 7cm. ,non small cell lung cancer -,docetaxel is indicated for the treatment of patients with locally advanced or metastatic non small cell lung cancer, including those who have failed platinum-based chemotherapy. ,ovarian cancer - docetaxel is indicated for the treatment of metastatic carcinoma of the ovary after failure of first-line or subsequent chemotherapy. ,prostate cancer -,docetaxel is indicated for the treatment of patients with androgen independent (hormone refractory) prostate cancer. ,head and neck cancer -,docetaxel, in combination with cisplatin and fluorouracil is indicated as induction treatment prior to chemoradiotherapy, for the treatment of patients with locally advanced, squamous cell carcinoma of the head and neck, who have low probability of surgical cure, require organ preservation or where the tumour is technically unresectable.